Profile data is unavailable for this security.
About the company
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-25.86m
- Incorporated2011
- Employees6.00
- LocationNeximmune Inc9119 Gaither RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (301) 825-9810
- Fax+1 (302) 636-5454
- Websitehttps://www.neximmune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Panbela Therapeutics Inc | 0.00 | -27.26m | 1.89m | 7.00 | -- | -- | -- | -- | -20.38 | -20.38 | 0.00 | -0.6563 | 0.00 | -- | -- | 0.00 | -201.94 | -215.89 | -809.38 | -476.38 | -- | -- | -- | -- | -- | -161.79 | 4.16 | -- | -- | -- | 27.68 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 2.09m | 0.00 | -- | 1.18 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 2.12m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Windtree Therapeutics Inc | 0.00 | -5.96m | 2.18m | 15.00 | 0.1986 | 0.1218 | -- | -- | 18.53 | 18.53 | 0.00 | 30.23 | 0.00 | -- | -- | 0.00 | -18.26 | -44.51 | -20.72 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -17.06m | 2.18m | 10.00 | -- | 0.38 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Neximmune Inc | 0.00 | -25.86m | 2.23m | 6.00 | -- | 0.8149 | -- | -- | -24.16 | -24.16 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -130.41 | -115.07 | -183.16 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 2.46m | 12.00 | -- | -- | -- | 5.48 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Tharimmune Inc | 0.00 | -8.89m | 2.46m | 2.00 | -- | 0.349 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 2.48m | 15.00 | -- | 0.1252 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Aclarion Inc | 60.05k | -6.13m | 2.50m | 6.00 | -- | 0.8714 | -- | 41.69 | -7.41 | -7.41 | 0.0341 | 0.3502 | 0.0215 | -- | 3.50 | 10,008.33 | -219.26 | -- | -337.53 | -- | -29.49 | -- | -10,203.20 | -- | -- | -- | 0.211 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Qrons Inc | 0.00 | -763.52k | 2.53m | 2.00 | -- | -- | -- | -- | -0.0562 | -0.0562 | 0.00 | -0.1078 | 0.00 | -- | -- | 0.00 | -18,782.78 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -19.02 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| Virax Biolabs Group Ltd | 0.00 | -1.71m | 2.60m | 5.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.8568 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 0.0223 | -112.29 | -- | -- | -100.00 | -- | -162.50 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Mar 2024 | 59.85k | 4.37% |
| Slate Path Capital LPas of 31 Mar 2024 | 37.00k | 2.70% |
| EPIQ Capital Group LLCas of 31 Mar 2024 | 15.62k | 1.14% |
| PNC Bank, NA (Investment Management)as of 31 Mar 2024 | 12.64k | 0.92% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 12.01k | 0.88% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 10.80k | 0.79% |
| Geode Capital Management LLCas of 31 May 2024 | 4.19k | 0.31% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.58k | 0.12% |
| Dimensional Fund Advisors LPas of 30 Apr 2024 | 1.16k | 0.08% |
| RBC Dominion Securities, Inc.as of 31 Mar 2024 | 173.00 | 0.01% |
